Carnegie Capital Asset Management, LLC Crispr Therapeutics Ag Transaction History

Carnegie Capital Asset Management, LLC

$3.18 Billion
Q2 2024

A detailed history of Carnegie Capital Asset Management, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Carnegie Capital Asset Management, LLC holds 102,112 shares of CRSP stock, worth $4.56 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

102,112

Previous 67,612 51.03%

Holding current value

$4.56 Million

Previous $4.61 Million 19.68%

% of portfolio

0.17%

Previous 0.14%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 19, 2024	BUY	$51.17 - $68.18 $1.77 Million - $2.35 Million	34,500 Added 51.03%	102,112 $5.52 Million
Q1 2024 May 03, 2024	SELL	$60.67 - $89.12 $359,469 - $528,036	-5,925 Reduced 8.06%	67,612 $4.61 Million
Q4 2023 Jan 29, 2024	SELL	$38.62 - $72.18 $586,251 - $1.1 Million	-15,180 Reduced 17.11%	73,537 $4.6 Million
Q3 2023 Oct 10, 2023	BUY	$45.39 - $59.0 $1.27 Million - $1.64 Million	27,875 Added 45.82%	88,717 $4.03 Million
Q2 2023 Aug 04, 2023	BUY	$43.47 - $67.77 $2.64 Million - $4.12 Million	60,842 New	60,842 $3.42 Million
Q4 2022 Jan 23, 2023	SELL	$39.19 - $65.67 $1.28 Million - $2.15 Million	-32,700 Reduced 56.01%	25,682 $0
Q3 2022 Oct 13, 2022	SELL	$61.1 - $83.78 $1.76 Million - $2.41 Million	-28,770 Reduced 33.01%	58,382 $3.82 Million
Q2 2022 Aug 02, 2022	SELL	$43.23 - $73.83 $1.3 Million - $2.22 Million	-30,020 Reduced 25.62%	87,152 $5.3 Million
Q2 2022 Jul 13, 2022	BUY	$43.23 - $73.83 $1.34 Million - $2.29 Million	31,009 Added 35.99%	117,172 $19 Million
Q1 2022 Apr 11, 2022	SELL	$53.19 - $79.24 $1.71 Million - $2.55 Million	-32,189 Reduced 27.2%	86,163 $5.41 Million
Q4 2021 Jan 21, 2022	SELL	$70.09 - $111.29 $40,301 - $63,991	-575 Reduced 0.48%	118,352 $8.97 Million
Q3 2021 Oct 08, 2021	BUY	$110.2 - $156.64 $193,401 - $274,903	1,755 Added 1.5%	118,927 $13.3 Million
Q2 2021 Jul 16, 2021	BUY	$100.84 - $161.89 $775,560 - $1.25 Million	7,691 Added 7.02%	117,172 $19 Million
Q1 2021 Apr 12, 2021	BUY	$110.72 - $210.04 $1.69 Million - $3.21 Million	15,289 Added 16.23%	109,481 $13.3 Million
Q4 2020 Feb 08, 2021	BUY	$79.67 - $173.23 $392,534 - $853,504	4,927 Added 5.52%	94,192 $14.4 Million
Q3 2020 Oct 13, 2020	SELL	$78.5 - $100.64 $192,717 - $247,071	-2,455 Reduced 2.68%	89,265 $7.47 Million
Q2 2020 Jul 09, 2020	BUY	$38.5 - $76.05 $980,210 - $1.94 Million	25,460 Added 38.42%	91,720 $6.74 Million
Q1 2020 May 08, 2020	BUY	$33.68 - $62.53 $964,932 - $1.79 Million	28,650 Added 76.18%	66,260 $2.81 Million
Q4 2019 Feb 13, 2020	BUY	$36.68 - $73.13 $456,299 - $909,737	12,440 Added 49.42%	37,610 $2.29 Million
Q3 2019 Nov 20, 2019	BUY	$40.99 - $52.56 $105,344 - $135,079	2,570 Added 11.37%	25,170 $1.03 Million
Q2 2019 Jul 24, 2019	BUY	$35.45 - $48.2 $801,170 - $1.09 Million	22,600 New	22,600 $1.06 Million

Others Institutions Holding CRSP

# of Institutions

523

Shares Held

58M

Call Options Held

1.73M

Put Options Held

1.84M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.48B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Carnegie Capital Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Carnegie Capital Asset Management, LLC with notifications on news.

Account

Carnegie Capital Asset Management, LLC Crispr Therapeutics Ag Transaction History